Citations

Mayo Clinic

Showing 10 of 108599 citations.

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
Patel, Krina K. , Manier, Salomon , Solomon, Scott R. , Chen, Christine , Delforge, Michel, Larsen, Jeremy T. , Suzuki, Kenshi , Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Mateos, María‐Victoria , Rodríguez‐Otero, Paula , Baz, Rachid , Raab, Marc S. , Cavo, Michèle , Callander, Natalie S. , Costa, Luciano J. , Moreau, Philippe , Raje, Noopur , Scheid, Christof , Pabst, Thomas , Cook, Mark , Giralt, Sergio

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e369897b

10.1097/01.hs9.0000967692.36989.7b Get It

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
Gorak, Edward J., Otterstatter, Michael , Baghdadi, Tareq Al, Foran, James M. , Liu, Jane Jijun, Gore, Steven D. , Kroft, Steven H. , Saber, Wael , Rollison, Dana E. , Wilson, Steffanie H, Thompson, Jason, Borchert, Christine, Hebert, Donnie, Walker, Mary E. , Padron, Eric , Wilson, Stephanie H. , Gillis, Nancy , Bejar, Rafael , Kroft, Steven H , Zhang, Ling , Sherman, Seth , Sekeres, Mikkael A , Otterstatter, Michael , Baghdadi, Tareq Al , Harrington, Alexandra, Starczynowski, Daniel T. , Zhang, Ling , Moscinski, Lynn C. , Dezern, Amy Elizabeth , Sekeres, Mikkael A.

Blood Advances | August 8, 2023 | Volume: 7 | Issue: 20 | Pages: 6120-6129

10.1182/bloodadvances.2023010061 | PMID 37552083 Get It

Abstract Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying dysplasia. We compared local clinical site diagnoses with central, adjudicated review from 918 participants enrolled in the ongoing National Heart, Lung, and Blood Institute National MDS Natural History Study, a prospective observational cohort study of participants with suspected MDS or MDS/myeloproliferative neoplasms (MPNs). Locally, 264 (29%) were diagnosed as having MDS, 15 (2%) MDS/MPN overlap, 62 (7%) idiopathic cytopenia of undetermined significance (ICUS), 0 (0%) acute myeloid leukemia (AML) with <30% blasts, and 577 (63%) as other. Approximately one-third of cases were reclassified after central review, with 266 (29%) diagnosed as MDS, 45 (5%) MDS/MPN overlap, 49 (5%) ICUS, 15 (2%) AML with <30%, and 543 (59%) as other. Site miscoding errors accounted for more than half (53%) of the local misdiagnoses, leaving a true misdiagnosis rate of 15% overall, 21% for MDS. Therapies were reported in 37% of patients, including 43% of patients with MDS, 49% of patients with MDS/MPN, and 86% of patients with AML with <30% blasts. Treatment rates were lower (25%) in cases with true discordance in diagnosis compared with those for whom local and central diagnoses agreed (40%), and receipt of inappropriate therapy occurred in 7% of misdiagnosed cases. Discordant diagnoses were frequent, which has implications for the accuracy of study-related and national registries and can lead to inappropriate therapy. This trial was registered at www.clinicaltrials.gov as #NCT05074550.
T2*-weighted 7-T Imaging of Cerebral Cavernous Malformations
Lakhani, Dhairya A. , Middlebrooks, Erik H. , Middlebrooks, Erik H , Lakhani, Dhairya

Radiology | August 8, 2023 | Volume: 308 | Issue: 2 | Pages: No page available

10.1148/radiol.230856 | PMID 37552085 Get It

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
Harrison, Claire , Kremyanskaya, Marina , Sanabria, Fabián , Marsousi, Niloufar , Giuseppi, Ana Carolina, Jiang, Huijing, Palmer, Jeanne , McCaul, Kelly, Gerds, Aaron T. , Kiladjian, Jean‐Jacques , Mesa, Ruben A. , Vannucchi, Alessandro M. , Komrokji, Rami S. , Bose, Prithviraj , Mead, Adam J. , Gotlib, Jason , Sanabria, Fabian, Ribrag, Vincent , Verstovšek, Srđan , Passamonti, Francesco

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e0882611

10.1097/01.hs9.0000967580.08826.11 Get It

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
Patriarca, Andrea, Rivera, Candido E., Granacher, Nikki, Palmer, Jeanne , Rampal, Raajit K. , Eliane, Jean-Pierre, Chang, Tzuu-Wang, Klein, Sandra, Colak, Gozde , Harrison, Claire , Passamonti, Francesco , Patriarca, Andrea , Knapper, Steven , Scandura, Joseph Michael , Devos, Timothy , Mead, Adam J. , Oh, Stephen T. , Teichmann, Lino Lars , Li, Qing

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e9927843

10.1097/01.hs9.0000967584.99278.43 Get It

S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703
Wieduwilt, Matthew J. , Yin, Jun , Kour, Oudom, Teske, Rebecca, Byrd, Ken, Doucette, Kimberly, Mangan, James K. , Jamieson, Katarzyna , Dinner, Shira, Bseiso, Ali W., Litzow, Mark R. , Stone, Richard M. , Stock, Wendy , Byrd, Ken, Masters, Gregory A. , Mims, Alice S , Uy, Geoffrey L. , Erba, Harry Paul

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e08838b7

10.1097/01.hs9.0000967380.08838.b7 Get It

Contrast-Induced Encephalopathy in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis
Davis, Paul W. , Krisanapan, Pajaree , Tangpanithandee, Supawit , Miao, Jing , Hassanein, Mohamed , Acharya, Prakrati , Mao, Michael A. , Craici, Iasmina , Cheungpasitporn, Wisit , Miao, Jing , Mao, Michael A , Craici, Iasmina M, Cheungpasitporn, Wisit , Tangpanithandee, Supawit , Krisanapan, Pajaree , Thongprayoon, Charat , Hassanein, Mohamed

Medicines | August 8, 2023 | Volume: 10 | Issue: 8 | Pages: 46

10.3390/medicines10080046 | PMID 37623810 Get It

Background: Contrast-induced encephalopathy (CIE) is an infrequent but serious neurological condition that occurs shortly after the administration of contrast during endovascular and angiography procedures. Patients suffering from chronic kidney disease (CKD) or end-stage kidney disease (ESKD) are considered to be at a higher risk of contrast medium neurotoxicity, due to the delayed elimination of the contrast medium. However, the occurrence and characteristics of CIE in CKD/ESKD patients have not been extensively investigated. Methods: We conducted a comprehensive literature search, utilizing databases such as MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, up to September 2022. The purpose was to identify documented cases of CIE among patients with CKD or ESKD. Employing a random-effects model, we calculated the pooled incidence and odds ratio (OR) of CIE in CKD/ESKD patients. Results: Our search yielded a total of eleven articles, comprising nine case reports and two observational studies. Among these studies, 2 CKD patients and 12 ESKD patients with CIE were identified. The majority of the CKD/ESKD patients with CIE (93%) had undergone intra-arterial contrast media and/or endovascular procedures to diagnose acute cerebrovascular disease, coronary artery disease, and peripheral artery disease. The male-to-female ratio was 64%, and the median age was 63 years (with an interquartile range of 55 to 68 years). In the two observational studies, the incidence of CIE was found to be 6.8% in CKD patients and 37.5% in ESKD patients, resulting in a pooled incidence of 16.4% (95% CI, 2.4%–60.7%) among the CKD/ESKD patients. Notably, CKD and ESKD were significantly associated with an increased risk of CIE, with ORs of 5.77 (95% CI, 1.37–24.3) and 223.5 (95% CI, 30.44–1641.01), respectively. The overall pooled OR for CIE in CKD/ESKD patients was 32.9 (95% CI, 0.89–1226.44). Although dialysis prior to contrast exposure did not prevent CIE, approximately 92% of CIE cases experienced recovery after undergoing dialysis following contrast exposure. However, the effectiveness of dialysis on CIE recovery remained uncertain, as there was no control group for comparison. Conclusions: In summary, our study indicates an association between CIE and CKD/ESKD. While patients with CIE showed signs of recovery after dialysis, further investigations are necessary, especially considering the lack of a control group, which made the effects of dialysis on CIE recovery uncertain.
The Value of Pharmacogenomics for White and Indigenous Americans after Kidney Transplantation
Brady, Alexandra, Misra, Suman , Abdelmalek, Mina, Kekić, Adrijana, Lim, Elisabeth S. , Jakob, Nicholas, Keddis, Mira T. , Kunze, Katie, Lim, Elisabeth, Keddis, Mira , Kunze, Katie L. , Mour, Girish

Pharmacy | August 8, 2023 | Volume: 11 | Issue: 4 | Pages: 125

10.3390/pharmacy11040125 | PMID 37624080 Get It

Background: There is a paucity of evidence to inform the value of pharmacogenomic (PGx) results in patients after kidney transplant and how these results differ between Indigenous Americans and Whites. This study aims to identify the frequency of recommended medication changes based on PGx results and compare the pharmacogenomic (PGx) results and patients’ perceptions of the findings between a cohort of Indigenous American and White kidney transplant recipients. Methods: Thirty-one Indigenous Americans and fifty White kidney transplant recipients were studied prospectively. Genetic variants were identified using the OneOme RightMed PGx test of 27 genes. PGx pharmacist generated a report of the genetic variation and recommended changes. Pre- and post-qualitative patient surveys were obtained. Results: White and Indigenous American subjects had a similar mean number of medications at the time of PGx testing (mean 13 (SD 4.5)). In the entire cohort, 53% received beta blockers, 30% received antidepressants, 16% anticoagulation, 47% pain medication, and 25% statin therapy. Drug–gene interactions that warranted a clinical action were present in 21.5% of patients. In 12.7%, monitoring was recommended. Compared to the Whites, the Indigenous American patients had more normal CYP2C19 (p = 0.012) and CYP2D6 (p = 0.012) activities. The Indigenous American patients had more normal CYP4F2 (p = 0.004) and lower VKORC (p = 0.041) activities, phenotypes for warfarin drug dosing, and efficacy compared to the Whites. SLC6A4, which affects antidepressant metabolism, showed statistical differences between the two cohorts (p = 0.017); specifically, SLC6A4 had reduced expression in 45% of the Indigenous American patients compared to 20% of the White patients. There was no significant difference in patient perception before and after PGx. Conclusions: Kidney transplant recipients had several drug–gene interactions that were clinically actionable; over one-third of patients were likely to benefit from changes in medications or drug doses based on the PGx results. The Indigenous American patients differed in the expression of drug-metabolizing enzymes and drug transporters from the White patients.